Cybin to present an abstract and moderate a psychedelic workshop at the 6th annual neuropsychiatric drug development summit

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its abstract describing a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines has been selected for presentation at the neuropsychiatric drug development summit taking pla.
CYBN Ratings Summary
CYBN Quant Ranking